Clinical Efficacy and Transcriptomic Analysis of Congrong Shujing Granules () in Patients with Parkinson's Disease and Syndrome of Shen (Kidney) Essence Deficiency.
10.1007/s11655-020-3080-0
- Author:
Shi-Ya CHEN
1
;
Shao-Jian XIAO
1
;
You-Ning LIN
1
;
Xi-Yu LI
1
;
Qian XU
2
;
Sha-Sha YANG
2
;
Lian-Hong HUANG
3
;
Jing CAI
4
Author Information
1. Geriatrics Department, the Third Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China.
2. College of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China.
3. College of Medical Technology and Engineering, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
4. Geriatrics Department, the Third Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China. caij1@163.com.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
Congrong Shujing Granules;
Parkinson’s disease;
RNA-sequencing;
randomized controlled trial;
transcriptomics
- From:
Chinese journal of integrative medicine
2020;26(6):412-419
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To evaluate the clinical efficacy and safety of Congrong Shujing Granules ( , CSGs) in treating patients with Parkinson's disease (PD) and Chinese medicine (CM) syndrome of Shen (Kidney) essence deficiency, and to investigate the potential mechanism involving efficacy through a transcriptome sequencing approach.
METHODS:Eligible PD patients with syndrome of Shen essence defificiency were randomly assigned to a treatment group or a control group by a random number table, and were treated with CSGs combined with Western medicine (WM), or placebo combined with WM, respectively. Both courses of treatment lasted for 12 weeks. The Unifified Parkinson's Disease Rating Scale (UPDRS) score, the PD Question-39 (PDQ-39) score, CM Syndrome Scale score, and drug usage of all patients were evaluated before and after treatment. Safety was evaluated by clinical laboratory tests and electrocardiographs. Blood samples from 6 patients in each group were collected before and after the trial and used for transcriptomic analysis by gene ontology analysis and Kyoto Encyclopedia of Genes and Genomes pathway analysis. Differentially expressed genes were validated using reverse transcription-polymerase chain reaction.
RESULTS:A total of 86 PD patients were selected from the Third Affifiliated People's Hospital of Fujian University of Traditional Chinese Medicine between January 2017 and December 2017. Finally, 72 patients completed the trial, including 35 in the treatment group and 37 in the control group. When compared with the control group after treatment, patients in the treatment group showed signifificant decreases in UPDRS sub-II score, PDQ-39 score, CM syndrome score, and Levodopa equivalent dose (P<0.05). During the treatment course, no signifificant changes were observed in safety indicators between the two groups (P>0.05). A possible mechanism of clinical effificacy was proposed that involved regulating cell metabolism-related processes and ribosome-related pathways. Treatment with CSGs had shown to affect relevant gene loci for PD, including AIDA, ANKRD36BP2, BCL2A1, BCL2L11, FTH1P2, GCH1, HPRT1, NFE2L2, RMRP, RPS7, TGFBR1, WIPF2, and COX7B.
CONCLUSIONS:CSGs combined with WM can be used to treat PD patients with CM syndrome of Shen essence defificiency with a good safety. The possible mechanism of action and relevant gene loci were proposed. (Registration No. ChiCTR-IOR-16008394).
